source
- Altimmune to discuss Phase 3 design for alcohol use disorder drug with FDAAltimmune is preparing to meet the FDA in December to discuss the design of a pivotal Phase 3 trial for its glucagon/GLP-1 dual receptor agonist pemvidutide. The Phase 2 RECLAIM study enrolled abo…
- AbCellera halts development of OX40 antibody ABCL575 after phase-1 trialAbCellera announced it will not move ABCL575 beyond phase 1, ending its OX40 program. The phase-1 study met its endpoints, showing a favorable tolerability profile and pharmacokinetics that suppor…